Int J App Pharm, Vol 11, Issue 5, 2019, 54-59Original Article


FORMULATION AND EVALUATION OF QUERCETIN NANOPARTICLE GEL FOR OSTEOARTHRITIS

DEANTARI KARLIANA¹, EFFIONORA ANWAR², ANTON BAHTIAR¹

¹Department of Pharmacology and Toxicology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok 16424, Indonesia. ²Department of Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Kampus UI Depok 16424, Indonesia
Email: anton.bahtiar@farmasi.ui.ac.id

Received: 22 Mar 2019, Revised and Accepted: 06 Jun 2019

ABSTRACT

Objective: To analyze the effects of the topical gel that consists of quercetin nanoparticles on the mono iodoacetate-induced osteoarthritis.

Methods: Injection of lecithin-quercetin into chitosan-tocopheryl polyethylene glycol succinate (TPGS) was used to prepared quercetin nanoparticle. Evaluation parameter for the quercetin nanoparticle including polydispersity index, zeta potential, particle size using particle size analyzer and morphology were executed using a transmission electron microscope. The evaluation of quercetin nanoparticle gel includes organoleptic and also a homogeneity of quercetin nanoparticle gel includes pH and viscosity. Quercetin nanoparticle gel was given for osteoarthritis (OA) animal model. The amount dosage of quercetin nanoparticle used in this study was 0.84, 1.68, and 3.37 mg/g gel. Measurement of the edema volume was conducted on day 7, 14, 21, 28, 35, 42, 49, 56, 63, and 70.

Results: The quercetin nanoparticle gel dosage 1, 2, and 3 could reduce inflammation on two osteoarthritis animal models. On DMM group, 14 d after the treatment, there were significant differences between negative group and dosage 3 (P=0.028) and A. conyzoides extract gel (P=0.015). It has shown that injection of mono iodoacetate intraarticularly significantly increased the volume of edema in all groups that had been given by mono iodoacetate on day 7 to day 28. On the 42 d after administration of quercetin nanoparticle gel, there were significant differences between the normal and dosage 3 group (P= 0.000).

Conclusion: Quercetin nanoparticle gel could reduce inflammation and prevent cartilago damage on histological evaluation.

Keywords: Quercetin, Osteoarthritis, Nanoparticle, Formulation

© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open-access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
DOI: http://dx.doi.org/10.22159/ijap.2019v11i5.33191

INTRODUCTION

Osteoarthritis (OA) is a disease with several characteristics, including joint pain, definite motion, and also inflammation without systemic effect. Inflammation also the key modulator on the pathology of osteoarthritis, therefore inflammation could be the targeted therapy for osteoarthritis [1, 2]. Chondrocytes of knee osteoarthritis can increase the activity and production of inflammatory cytokines, which are also made by other joint tissues [3]. The purpose of osteoarthritis therapy is to improve joint caused by inflammation and reduce patient, particularly pain from daily activity. Pain aggressing joint can become worst because of joint motion. OA symptoms such as stiffness of joints, chronic pain, and muscle weakness, are the serious risk factor for patients with osteoarthritis with outcomes of impaired quality and also mobility limitation [4].

Nowadays, osteoarthritis therapy includes non-pharmacology therapy and surgery. The first therapy for osteoarthritis is Nonsteroidal Anti-Inflammatory Drugs (NSAID). However, NSAID has several side effect, including gastrointestinal [5] and cardiovascular risk [6]. It is recommended by Osteoarthritis Research Society International (OARSI) that NSAID should be avoided for prolonged use as much as possible [7]. Topical antiinflammation could be the solution to reduce the severity of OA.

Quercetin is one of flavonoid compound that has been isolated and used for the compliment on therapy of disease [8]. On in vitro studies, it showed anti-inflammatory activity because of its ability to inhibited cyclooxygenase (COX) and lipoxygenase (LOX) [9]. Quercetin could also suppress proinflammatory cytokines in cultured fibroblasts on in vivo experiments [10]. However, research about the anti-inflammation effect of quercetin in the topical application has not been discovered yet.

Nanoparticle becomes a potential option for topical drug delivery because of its unique characteristics. Since the increase of surface area, the nanoparticle has higher efficiency to increase drug permeation into the skin. Lecithin-Chitosan Nanoparticle is a promising vehicle in topical drug delivery because of the negative charge in lecithin and positive charge in chitosan bind firmly on human skin, and generate an effective drug delivery system [11].

In this study, the effects of the topical gel that consists of quercetin nanoparticles on the mono iodoacetate induced OA rats were analyzed to evaluate the pharmacodynamic effects.

MATERIALS AND METHODS

Methods

Soybean lecithin Phospholipon 90G (Lipoid GmbH, Germany) and quercetin (Sigma Aldrich, USA) were dissolved in ethanol 96%. Chitosan-TPGS solution achieved by dissolving chitosan (Sigma Aldrich, USA) and TPGS (Sigma Aldrich, USA) with 0.1% acetic acid [12]. The lecithin-quercetin solution was added into chitosan-TPGS solution using plastic needle tubing with 1000 rpm agitation for 30 min. The pH of nanoparticle was arranged until 4.5 using 0.5 M NaOH. The suspension then filtered through a membrane filter to eliminate unfused compound.

Table 1: Quercetin nanoparticle formula

Ingredients Formula 1 Formula 2 Formula 3
Lechitin (g/ml) 0.4% 0.4% 0.4%
Quercetin (g/ml) 0.06% 0.12% 0.24%
Chitosan (g/ml) 0.02% 0.02% 0.02%
TPGS (g/ml) 2% 2% 2%
Ethanol 96% (ml/ml) 8% 8% 8%
0.1% Acetic acid (ml/ml) 100% 100% 100%

The entrapment efficiency of quercetin nanoparticle was measured using High-Performance Liquid Chromatography (HPLC). The nanoparticle was centrifuged at 4500 rpm for 60 min. The collected precipitate calculate with a formula:

Entrapment Efficiency: x 100%

Qe: quercetin concentration on the precipitate

Qt: theoretical quercetin concentration

The concentration of quercetin was analyzed using HPLC with 370 nm wavelength.

In this study, particle size distribution, Zeta Potential, and Polydispersity Index were measured One ml of quercetin nanoparticle was added to the cuvet; Samples were analyzed with Particle Size Analyzer (PSA Malvern, UK). Based on the assessment of characterization of particle size distribution, zeta potential, and polydispersity index, one formula of quercetin nanoparticle will be selected and used to made quercetin nanoparticle gel.

Vesicle morphology was measured to one chosen formula of quercetin nanoparticle. The Quercetin nanoparticle was dropped into carbon copper grid form a thin layer, then added one drop of phosphotungstic acid 1%. Morphology and vesicle size was analyzed with a transmission electron microscope (JEOL JEM-1400, Japan) [13].

Table 2: Formulation of quercetin nanoparticle gel

Ingredients Quercetin nanoparticle gel dosage 1 Quercetin nanoparticle gel dosage 2 Quercetin nanoparticle gel dosage 3 A. conyzoides gel

Quercetin

Nanoparticle

Equivalent to quercetin

0.84 mg/g

Equivalent to quercetin

1.68 mg/g

Equivalent to quercetin

3.36 mg/g

 -
A. conyzoides Extract - - - A. conyzoides Extract 160 mg/g
Carbopol 940 1.5% 1.5% 1.5% 1.5%
Propilenglycol 5% 5% 5% 5%
Methylparaben 0.1% 0.1% 0.1% 0.1%
Butil Hidroxy Toluen (BHT) 0.02% 0.02% 0.02% 0.02%
Trietanolamin (TEA) 1.5% 1.5% 1.5% 1.5%
Aquadest Add 100% Add 100% Add 100% Add 100%

The dosage used was referring to the previous study of A. conyzoides extract with peroral treatment for osteoarthritis animal model [14]. The dosage which gives effect to the OA animal model was 160 mg of A. conyzoides leaves extract, which contains 0.84 mg quercetin. The amount of dosage used in this study was 0.84, 1.68, and 3.37 mg/g gel. A. conyzoides leaves extract was also used in this study. Carbopol 940 (Sumitomo Seika Chemical, Japan) and TEA were added into water. Methylparaben and BHT (Sterlitanak Petrochemical, Rusia) were dissolved into propylene glycol (Dow Chemical, Singapore), and was added into the carbopol. HCl 2 M was added to adjusted pH until it suited for skin (4.5-6.5). After the gel was formed, quercetin nanoparticle was mixed into the gel. The formulation of quercetin nanoparticle gel was evaluated, including visual organoleptic, smell, and color. Also, the homogeneity of quercetin nanoparticle gel, including pH and viscosity.

Preparation of the animal model was conducted using white male Sprague-Dawley rats (2-3 mo old) weighed 200-300 g purchased from Bogor Agricultural Institute, Indonesia. The animals were grouped and housed in acrylic cages and maintained on standard laboratory condition [temperature (25±2) °C] with dark and light cycle (12/12 h). This research had been certified by ethical certification of Faculty of Medicine, the University of Indonesia (UI FK No. 668/UN2. F1/ETIK/2017) for the use of animals in the experiment. Rats were divided into seven groups, with five rats per group. The groups consisted of 1 negative group, one normal group, one positive group, and four treatment groups.

Table 3: Group and treatment of the animal model

Group Number of rats Treatment on MIA OA model Treatment on DMM OA model
Normal group 5 Day-0 were given 0.05 ml saline solution Day-0 were given open knee surgery without DMM and at day 29-70 were given 1 g of clear gel
Negative group 5 Day-0 were given 0.05 ml MIA Day-0 were given DMM surgery and at day 29-70 were given 1 g of clear gel
Positive group 5 Day-0 were given 0.05 ml MIA and at day 29-70 were given 1 g sodium diclofenac gel Day-0 were given DMM surgery and at day 29-70 were given 1 g sodium diclofenac gel
Nanoparticle gel dosage 1 5 Day-0 were given 0.05 ml MIA and at day 29-70 were given 1 g quercetin nanoparticle gel dosage 1 Day-0 were given DMM surgery and at day 29-70 were given 1 g quercetin nanoparticle gel dosage 1
Nanoparticle gel dosage 2 5 Day-0 were given 0.05 ml MIA and at day 29-70 were given 1 g quercetin nanoparticle gel dosage 2 Day-0 were given DMM surgery and at day 29-70 were given 1 g quercetin nanoparticle gel dosage 2
Nanoparticle Gel dosage 3 5 Day-0 were given 0.05 ml MIA and at day 29-70 were given 1 g quercetin nanoparticle gel dosage 3 Day-0 were given DMM surgery and at day 29-70 were given 1 g quercetin nanoparticle gel dosage 3
A. conyzoides gel 5 Day-0 were given 0.05 ml MIA and at day 29-70 were given 1 g A. conyzoides gel Day-0 were given DMM surgery and at day 29-70 were given 1 g A. conyzoides gel

All the group of treatment, positive and negative of MIA OA model were induced intraarticularly with three mg/0.05 ml mono iodoacetate on 0.9% saline. The normal group was given 0.9% saline. In treatment with DMM OA model, rats were given DMM surgery. The normal group of DMM OA model was only given open knee surgery without DMM.

The normal group was given clear gel without nanoparticle quercetin, the positive group was given sodium diclofenac gel (Voltaren®), three doses variation of quercetin nanoparticle gel, and A. conyzoides group was given A. conyzoides gel with 160 mg/g gel on day 29 until 70 as seen on table 3. Measurement of edema volume in day 7,14,21,28, 35, 42, 49, 56, 63 and 70 using plethysmometer.

Statistical calculation was analyzed by One-way ANOVA, followed by multiple comparison tests. P value<0.05 were considered to be significant (P denoted probability). Statistics software (SPSS version 24) was used for statistical analysis. The data represented mean±standard error of the mean.

RESULTS

The visual observation of quercetin nanoparticles formula 1, 2, and 3, respectively shown in fig. 1. The yellow color of nanoparticle was achieved from the color of quercetin powder. Quercetin nanoparticle had a translucent yellow with slightly more yellow color on the higher dose of quercetin. It had a specific aroma of quercetin.

One of the main physique characteristics of a nanoparticle is the particle size. In this research, particle size was measured by Particle Size Analyzer. Z-average size of formula 1, 2, and 3 respectively 242.2 nm, 215.6 nm, and 212.2 nm. Polydispersity index of formula 1,2 and 3 respectively were 0.474, 0.460, and 0.405. It showed that nanoparticle quercetin formula 3 had the smallest Z-average size and polydispersity index (0.405) compared with formula 1 and 2.

Fig. 1: Visual observation of quercetin nanoparticle suspension, A: quercetin nanoparticle formula 1; B: quercetin nanoparticle formula 2; C: quercetin nanoparticle formula 3

Table 4: Zeta potential result of quercetin nanoparticle

Quercetin nanoparticle dosage Zeta potential (m/V)
Formula 1 +19.5±0.45
Formula 2 +24.0±1.55
Formula 3 +26.5±0.30

*Data given in mean±SD

Zeta potential more than (+/-) 30 m/V proven to be more stable in colloid and could resist aggregation between the particles because the higher the value of zeta potential the bigger the production of electrostatic deduction [15]. All of the quercetin nanoparticles had zeta potential under+30 m/V. This may occur as a result of electrostatic attraction between acidic phenolic OH group of quercetin and a positive load of the particle, and produce load distribution, making the low zeta potential value on the system. Based on the measurement of zeta potential in this study, formula 3 had the most significant zeta potential (+26,5±0.30 m/V) which indicated that formula 3 was the most stable formula besides formula 1 and 2.

Table 5: Entrapment efficiency of quercetin nanoparticle

Quercetin nanoparticle Entrapment efficiency (%)* Amount of quercetin
Formula 1 60.28±0.48 0.36 mg/ml
Formula 2 62.83±0.25 0.75 mg/ml
Formula 3 41.41±0.33 0.994 mg/ml

*Data given in mean±SD

Fig. 2: Vesicle morphology of nanoparticle quercetin formula 3

The entrapment of efficiency in this study was performed using the direct method calculated by compared quercetin concentration on the precipitate and theoretical concentration on formula. The amount of quercetin had been used on formula 1, 2, and 3 respectively were 0.06%, 0.12%, and 0.24% (w/v). The entrapment of efficiency gel was shown in table 5. The higher entrapment efficiency of quercetin nanoparticle was on formula 2, but the highest amount of nanoparticle entrapped on suspension was formula 3, and it showed the best result on Z-average size, index polydispersity, and zeta potential among the others. Therefore, quercetin nanoparticle formula 3 was the chosen formula for quercetin nanoparticle gel.

Morphology of quercetin nanoparticles was observed under a transmission electron microscope. The results of the observation showed that the nanoparticle was spherical. The nanoparticle size from the photograph showed that the nanoparticle was around 200 nm and it matched with the result of Z-average size of the quercetin nanoparticle formula 3.

Fig. 3: Visual observation of gel, A: clear gel; B: quercetin nanoparticle gel dosage 1; C: quercetin nanoparticle gel dosage 2; D: quercetin nanoparticle gel dosage 3

Quercetin nanoparticle gel had a bright yellow color on every dose. There was a slight difference of yellow color between dosage 1, 2, and 3 with the densest yellow color is in nanoparticle gel dosage 3. The yellow color was achieved from the quercetin nanoparticle.

A topical gel must be in the pH range that is suitable for the skin, which is 4.5-6.5. The pH of quercetin nanoparticle gel dosage 1, 2, and 3 respectively were 5.54, 5.60, and 5.58. All of the gel were qualified with a skin pH range. The viscosity of the quercetin nanoparticle gel was measured by Brookfield viscometer using spindle 6 with 10 rpm. The viscosity of the quercetin nanoparticle gel dosage 1,2, and 3 were respectively 54400 cps, 55200 cps, and 55600 cps.

Fig. 4: Edema profile during treatment in MIA Osteoarthritis model, *Significantly different with the normal group (p<0.05), #significantly different from the negative control group (p<0.05)

Fig. 5: Edema profile during treatment in DMM Osteoarthritis model, *Significantly different with normal group (p<0.05), #significantly different from the negative control group (p<0.05)

In this study, there were seven groups of treatment on each model of osteoarthritis. The normal group consisted of no osteoarthritis rats, and also the negative group consisted of osteoarthritis rats were given clear gel without nanoparticle quercetin. Three different doses of nanoparticle were given to osteoarthritis rats to determine the best dosage for the treatment. A. conyzoides gel group which is from the previous study proven to contained quercetin. A. conyzoides gel group reduced edema of osteoarthritis rats orally. The positive group was that the osteoarthritis rats were given sodium diclofenac gel (Voltaren®). Sodium diclofenac is a potent NSAID use for the treatment of degenerative joint diseases such as osteoarthritis and rheumatoid arthritis [16]. On the previous study, sodium diclofenac gel was proven effective for relieving symptom on osteoarthritis [17]. The treatment was given on day 29 until 70.

Edema volume measurement was measured on day 0, 7, 14, 21, 28, 35, 42, 49, 56, 63, and 70. Edema volume was measured to determine changes in the volume of edema in animals with osteoarthritis before and after the treatments. On DMM group, 14 d after treatment, there were significant differences between negative group and dosage 3 (P=0.028) and A. conyzoides extract gel (P=0.015). On MIA group, it showed that injection of mono iodoacetate intraarticularly significantly increased the volume of edema in all groups given by mono iodoacetate on day 7 to day 28. On the 42 d after administration of quercetin nanoparticle gel, there were significant differences between the normal group and dosage 3 (P= 0.000).

DISCUSSION

In this study, a quercetin nanoparticle gel was given for OA animal model. Nanoparticle becomes the preference for a delivery system of topical drugs because of its typical characteristic. Since the increasing for its surface, a nanoparticle has a higher efficiency to increase drug permeation into the skin [18]. The preparation of nanoparticle consisted of soybean lecithin, chitosan, and TPGS results in good form of the nanoparticle. Lecithin is a natural phospholipid used for the variety of nanoparticle delivery vehicles, such as liposomes, micelles, and nanoparticles, and classified as a safe and biocompatible excipient [19, 20]. Chitosan is a polycationic polymer with mainly of glucosamine units that could tie the negatively charged substance resulting in a core-shell nanostructure and proven to be a promising carrier for drugs [21]. It has been reported that lecithin and chitosan can be formed a perfect round nanoparticle by the electrostatic interaction of chitosan polycationic and charge negative of lecithin. The molecule of lecithin formed a core and molecule of chitosan formed the hydrophilic shell layer to protect the inner structure [22]. The injection of lecithin into chitosan aqueous solution from the previous studies could exhibit an excellent spherical shape of nanoparticle and has better stability in the 20:1 ratio (lecithin: chitosan) [23].

The hydrophobic group on TPGS and lecithin molecules tied into each other and formed the hydrophobic core of the nanoparticle. Because of the lipophilicity of quercetin, quercetin should disperse on the hydrophobic core, and protected by the outer shell layer. TPGS had a crucial role in quercetin nanoparticle formulation by intruding stratum corneum to reduce the barrier of the skin and facilitating drug diffusion through the barrier layer. TPGS can also add the diffusion coefficient of nanoparticle between skin and vehicle [24, 25]. In the previous study, TPGS was used as a stabilizer for nanoparticles [26-28].

Polydispersity Index (PDI) less than 0.5 until approaches 0 indicated a low heterogeneity and a homogenous size particle. Measurement of particle size with PDI less than 0.5 was measured using Z-average. On the other way, if a sample has PDI more than 0.5, it is measured using the diameter by volume (DV) to measure the particle size distribution. The polydispersity index of all nanoparticle formula was less than 0.5. Therefore it was measured using Z-average to measure the particle size distribution. The Z-average of nanoparticle 1,2, and 3 respectively were 242.2 nm, 215.6 nm, and 212.2 nm.

The particle size of the sample is very affected by zeta potential. Zeta potential is a measure of potential electrostatic or capacity of repulsion between particles on a liquid suspension. Zeta potential is an important parameter that affected the stability of a dispersion system. Zeta potential could predict the aggregation or flocculation on suspension. Zeta potential of the nanoparticle respectively were+19.5±0.45,+24.0±1.55, and+26.5±0.30 m/V. Electrostatic attraction among the acidic phenolic OH group of quercetin and the positive charge particle affected the distribution of charges and caused a decreased of zeta potential of the system [29].

The vesicle morphology result of quercetin nanoparticle dosage 3 on Transmission Electron Microscope has shown that the quercetin nanoparticle was spherical. This result had matched with the previous study, which proven that lecithin and chitosan can form a perfect round nanoparticle. The vesicle size of nanoparticle was quite similar to the particle size measured by Particle Size Analyzer.

One of the primary purposes of osteoarthritis therapy is to escalate quality of life, such as relieving pain and reduce inflammation. The inflammation can develop due to the depletion layer of articular cartilage [30]. In this study, two of the osteoarthritis animal model were used. The DMM method is one of the animal model of Post Traumatic Osteoarthritis (PTOA) that causes inflammation. Higher mechanical loading of the medial compartment is the cause of increased incidence of medial compartment knee OA that changes the mechanical environment of the knee, and this has a profound influence on the initiation and progression of knee OA [31]. Intraarticularly injection of MIA inhibits glyceraldehyde-3-phosphate dehydrogenase activity in chondrocytes and causing cell death. It increases cytokines releases into the joint cavities and causing cartilage matrix damages [32]. The result of chondrocytes loss is morphological changes of articular cartilage, firmly in human osteoarthritis [33]. Another result is rapid inflammation and pain on day post-injection, and therefore, inflammation can serve as a measure of disease progression and also treatment outcomes in OA.

Edema volume was measured to observe the changes in the volume of edema in animals with osteoarthritis before and after the treatment. It had shown that injection of mono iodoacetate intraarticularly significantly increased the volume of edema in all groups that had been given mono iodoacetate on day 7 to day 28. On 42 d after administration of quercetin nanoparticle gel, there were significant differences between the negative group and dosage 3. Joint inflammation causes the influx of inflammatory cells and fluid to the inflamed area. The difference between edema of joint of negative group and quercetin nanoparticle group showed that quercetin had the anti-inflammation effects in OA animal model. In previous in vivo study, quercetin nanoparticle gel could prevent proteoglycan degradation by inhibits matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-13 (MMP-13), and a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5) expressions on OA rats [34]. In the previous in vitro study showed that quercetin could inhibit lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) production in macrophages [35]. Quercetin also has antiapoptotic and membrane protective effects [36]. Flavonoid has anti-inflammatory effects by inhibits the activity of enzyme cyclooxygenase (COX) and lipooxygenase (LOX) [37]. It also has the inhibition mechanism of leukocyte accumulation, histamine, and neutrophil degranulation [38].

CONCLUSION

In conclusion, the author had designed the quercetin nanoparticle gel for osteoarthritis rats. Nanoparticle lecithin chitosan vehicle could bring quercetin into the target sites and be able to reduced inflammation process by reducing the edema volume. Nanoparticle quercetin gel dosage 3 showed the best effication on osteoarthritis model of rats.

AUTHORS CONTRIBUTIONS

All the author have contributed equally

CONFLICTS OF INTERESTS

There are no conflicts of interest

REFERENCES

  1. Philp AM, Davis ET, Jones SW. Developing anti-inflammation therapeutics for patients with osteoarthritis. Rheumatology (Oxford) 2017;56:869-81.

  2. Heldari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and feature: Part I. Caspian J Int Med 2011;2:205-12.

  3. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opinion Rheumatol 2011;23:471-8.

  4. Likivainio T, Arokoski J. Physical function and properties of quadriceps femoris muscle in men with knee osteoarthritis. Arch Phys Med Rehabil 2008;89:2185–93.

  5. Pirmohamed M, James S, Meakin S. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15–9.

  6. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue. Cureus 2017;9:e1144.

  7. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.

  8. Kelly GS, Gregory S, Kelly ND. Quercetin monograph. Alternative Medicine Review 2011;16:172-94.

  9. Lee KM, Hwang MK, Lee DE, Lee KW, Lee HJ. Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J Agric Food Chem 2010;58:5815–20.

  10. Yoon JS, Chae MK, Lee SY, Lee EJ. Anti-inflammatory effect of quercetin in whole orbital tissue culture of graves' orbitopathy. Br J Ophthalmol 2012;1117–21.

  11. Wu X, Landfester K, Musyanovych A, Guy RH. Disposition of charged nanoparticles after their topical application to the skin. Skin Pharmacol Physiol 2010;23:117-23.

  12. Tan Q, Liu W, Guo C, Zhai, G. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 2011;6:1621-30.

  13. Zhu W, Yu A, Wang W, Dong R, Wu J, Zhai G. Formulation design of microemulsion for dermal delivery of penciclovir. Int J Pharm 2008;360:184-90.

  14. Bahtiar A, Nurazizah M, Roselina T, Tambunan AP, Arsianti A. Ethanolic extracts of baA. conyzoides leaves (Ageratum conyzoides L.) prevents inflammation and proteoglycan degradation by inhibiting TNF-a and MMP-9 on osteoarthritis rats induced by monosodium iodoacetate. Asian Pacific J Trop Med 2017;10:270-7.

  15. Mohanraj VJ, Chen Y. Nanoparticles–a review. Trop J Pharm Res 2006;5:561-73.

  16. Ahmed SI, Mangamoori LN, Rao YM. Formulation and characterization of matric and triple-layer matrix tablets for oral controlled drug delivery. Int J Pharm Pharm Sci 2010;2:137-43.

  17. Wadsworth LT, Kent JD, Holt RJ. Efficacy and safety of diclofenac sodium 2% topical solution for osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled, four-week study. Curr Med Res Opinion 2016;32:241-50.

  18. Choksi AN, Poonwalla T, Wilkerson MG. Nanoparticles: a closer look at their dermal effects. J Drugs Dermatol 2010;9:475-81.

  19. Pavelic Z, Skalko Basnet N, Filipovic Grcic J, Martinac A, Jalsenjak I. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Controlled Release 2005;106:34–43.

  20. Schubert MA, Harms M, Müller Goymann CC. Structural investigations on lipid NPs are containing high amounts of lecithin. Eur J Pharm Sci 2006;27:226–36.

  21. Sonvico F, Cagnani A, Rossi A, Motta S, Di Bari MT, Cavatorta F, et al. Formation of self-organized NPs by lecithin/chitosan ionic interaction. Int J Pharm 2006;324:67-73.

  22. Senyigit T, Sonvico F, Barbieri S, Ozer O, Santi P, Colombo P. Lecithin/chitosan NPs of clobetasol-17-propionate capable of accumulation in pigskin. J Controlled Release 2010;142:368-73.

  23. Fakhry A, Schneider GB, Zaharias R, Senel S. Chitosan supports the initial attachment and spreading of osteoblast preferentially over fibroblasts. Biomaterials 2004;25:2075-9.

  24. Zhu W, Guo C, Yua A, Gao Y, Cao F, Zhai G. Microemulsion-based hydrogel formulation of penciclovir for topical delivery. Int J Pharm 2009;378:152-8.

  25. El Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil emulsion: effects of cosurfactants. Int J Pharm 2008;355:285-92.

  26. Mishra PR, Al Shaal L, Muller RH, Keek CM. Production and characterization of hesperetin nanosuspension for dermal delivery. Int J Pharm 2009;37:182-9.

  27. Van Eerdenbrugh B, Van den Mooter G, Augustijn P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization, and transformation into solid products. Int J Pharm 2008;364:64-75.

  28. Baert L., van’t Klooster G, Dries W. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009;72:502-8.

  29. Liu W, Guo Y. Interaction between flavonoid, quercetin, and surfactant aggregates with different charges. J Colloid Interface Sci 2006;302:625-32.

  30. Bahtiar A, Sari FA, Audina M, Datunsolang NLC, Arsianti A. Ethanolic extracts of hedyotis corymbosa L. improves monosodium iodoacetate induce of osteoarthritis in rat. Asian J Pharm Clin Res 2017;10:473-6.

  31. Iijima H, Aoyama T, Ito A, Tajino J, Nagai M, Zhang X, et al. Destabilization of the medial meniscus leads to subchondral bone defects and site-specific cartilage degeneration in an experimental rat model. Osteoarthritis Cartilage 2014;22:1036-43.

  32. Im JS, Kim XL. Alteration of sensory neurons and spinal response to an experimental osteoarthritis pain model. Arthritis Rheumatism 2010;62:2995-3005.

  33. Janusz MJ, Hookfin EB, Heitmeyer SA, Woessner JF, Freemont AJ, Hoy-Land JA, et al. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. Osteoarthritis Cartilage 2001;9:751–60.

  34. Permatasari DA, Karliana D, Iskandarsyah, Arsianti A, Bahtiar A. Quercetin prevent proteoglycan destruction by inhibits matrix metalloproteinase-9, matrix metalloproteinase-13, a disintegrin and metalloproteinase with thrombospondin motifs-5 expressions on osteoarthritis model rats. J Adv Pharm Technol Res 2019;10:2-8.

  35. Manjeet KR, Ghosh B. Quercetin inhibits LPS-induced nitric oxide and tumor necrosis factor-alpha production in murine macrophages. Int J Immunopharmacol 1999;21:435–43.

  36. Zupanets IA, Shebeko SK, Popov OS. The effect of the medication diclocor containing diclofenac and quercetin, on clinical, biochemical parameters in rats with osteoarthritis. Int J Pharm Pharm Sci 2015;7:101-4.

  37. Kim HP, Mani I, Iversen L, Ziboh VA. Effects of naturally occurring flavonoids and bioflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostaglandins Leukotrienes Essential Fatty Acids 1998;58:17–24.

  38. Ribeiro D, Freitas M, Tome SM, Silva AM, Laufer S, Lima JL, et al. Flavonoids inhibit COX-1 and COX-2 enzymes and cytokine/chemokine production in whole human blood. Inflammation 2015;38:21491-4.